Other languages Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-28 EDT			5-day change	1st Jan Change
21.53 ^USD	+0.47%		-4.23%	-28.16%

06-28	Needham Trims Price Target on Rocket Pharmaceuticals to $52 From $53, Maintains Buy Rating	MT
06-28	Rocket Pharmaceuticals Says FDA Seeks More Information on Kresladi	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rocket Pharmaceuticals Says FDA Seeks More Information on Kresladi	06-28
US FDA declines to approve Rocket Pharma's immune disorder gene therapy	06-28
Rocket Pharmaceuticals, Inc. Provides Regulatory Update on KRESLADI? (marnetegragene autotemcel; marne-cel)	06-28
Rocket Pharmaceuticals Presents Positive Data from Lv Hematology Portfolio At the 27Th Annual Meeting of the American Society of Gene and Cell Therapy	05-10
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06
Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	04-16
Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	04-11
Rocket Pharmaceuticals Says European Medicines Agency Accepted Marketing Authorization Application for RP-L102	04-02
Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	04-02
Rocket Pharmaceuticals, Inc. Announces Executive Appointments	03-26
Rocket Pharmaceuticals Q4 Loss Narrows	02-26
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-25
Rocket Pharmaceuticals Says FDA Extends Review Timeline for Kresladi; Shares Decline	02-13
Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi? (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)	02-13
Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director	12-12
Rocket Pharmaceuticals Insider Sold Shares Worth $450,646, According to a Recent SEC Filing	11-17
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-05
Rocket Pharmaceuticals Insider Sold Shares Worth $315,744, According to a Recent SEC Filing	23-10-03
Rocket Pharmaceuticals' Biologics License Application for Gene Therapy Accepted by US FDA for Priority Review	23-10-02
Rocket Pharmaceuticals, Inc. Announces Fda Acceptance of Biologics License Application with Priority Review for Rp-L201 (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)	23-10-02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Other languages

Filters